{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:03:14Z","timestamp":1790492594448,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T00:00:00Z","timestamp":1380153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10147-013-0615-9","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T09:44:48Z","timestamp":1380102288000},"page":"753-760","source":"Crossref","is-referenced-by-count":24,"title":["Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"19","author":[{"given":"Asmaa M.","family":"Zahran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosny","family":"Badrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,26]]},"reference":[{"key":"615_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"615_CR2","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","volume":"110","author":"J Goldman","year":"2007","unstructured":"Goldman J (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110:2828\u20132837","journal-title":"Blood"},{"issue":"1","key":"615_CR3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5603\/FHC.2011.0022","volume":"49","author":"I Hus","year":"2011","unstructured":"Hus I, Tabarkiewicz J, Lewandowska M et al (2011) Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Folia Histochem Cytobiol 49(1):153\u2013160","journal-title":"Folia Histochem Cytobiol"},{"key":"615_CR4","first-page":"606","volume":"9","author":"AM Wolf","year":"2003","unstructured":"Wolf AM, Wolf D, Steurer M et al (2003) Increase of Tregs in the peripheral blood of cancer patients. Clin Cancer Res 9:606\u2013612","journal-title":"Clin Cancer Res"},{"key":"615_CR5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/sj.leu.2404522","volume":"21","author":"E Nadal","year":"2007","unstructured":"Nadal E, Garin M, Kaeda J et al (2007) Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 21:472\u2013479","journal-title":"Leukemia"},{"key":"615_CR6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ Tregs in immunological tolerance to self and non-self. Nat Immunol 6:345\u2013352","journal-title":"Nat Immunol"},{"issue":"1","key":"615_CR7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2249.2008.03858.x","volume":"156","author":"L Zhu","year":"2009","unstructured":"Zhu L, Chi L, Wang X et al (2009) Reduced circulating CD4+CD25+ cell populations in haemorrhagic fever with renal syndrome. Clin Exp Immunol 156(1):88\u201396","journal-title":"Clin Exp Immunol"},{"key":"615_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","volume":"212","author":"S Sakaguchi","year":"2006","unstructured":"Sakaguchi S, Ono M, Setoguchi R et al (2006) Foxp3+CD25+CD4+ natural Tregs in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8\u201327","journal-title":"Immunol Rev"},{"key":"615_CR9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2141.2010.08453.x","volume":"153","author":"E Bachy","year":"2011","unstructured":"Bachy E, Bernaud J, Roy P et al (2011) Quantitative and functional analyses of CD4+CD25+FoxP3+ Tregs in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br J Haematol 153:139\u2013143","journal-title":"Br J Haematol"},{"key":"615_CR10","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2174\/138161209788453211","volume":"15","author":"M Beyer","year":"2009","unstructured":"Beyer M, Schultze J (2009) Tregs: major players in the tumor microenvironment. Curr Pharm Des 15:1879\u20131892","journal-title":"Curr Pharm Des"},{"key":"615_CR11","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.2005.03.6830","volume":"24","author":"GG Cesana","year":"2006","unstructured":"Cesana GG, DeRaffele G, Cohen S (2006) Characterization of CD4+CD25+ Tregs in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169\u20131177","journal-title":"J Clin Oncol"},{"key":"615_CR12","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","volume":"169","author":"UK Liyanage","year":"2002","unstructured":"Liyanage UK, Moore TT, Joo HG (2002) Prevalence of Tregs is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756\u20132761","journal-title":"J Immunol"},{"key":"615_CR13","first-page":"4404","volume":"9","author":"F Ichihara","year":"2003","unstructured":"Ichihara F, Kono K, Takahashi A et al (2003) Increased populations of Tregs in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404\u20134408","journal-title":"Clin Cancer Res"},{"key":"615_CR14","doi-asserted-by":"crossref","unstructured":"Sasada T, Kimura M, Yoshida Y et al (2003) CD4+CD25+ Tregs in patients with gastrointestinal malignancies: possible involvement of Tregs in disease progression. Cancer 98:1089\u20131099","DOI":"10.1002\/cncr.11618"},{"key":"615_CR15","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","volume":"103","author":"N Marshall","year":"2004","unstructured":"Marshall N, Christie L, Munro L (2004) Immunosuppressive Tregs are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103:1755\u20131762","journal-title":"Blood"},{"key":"615_CR16","volume-title":"World health organization classification of tumours of haematopoitic and lymphoid tissue","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2008) World health organization classification of tumours of haematopoitic and lymphoid tissue. IARC Press, Lyon"},{"issue":"15","key":"615_CR17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S (2003) International randomised study of interferon versus STI571 (IRIS) study group frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423\u20131432","journal-title":"N Engl J Med"},{"key":"615_CR18","doi-asserted-by":"crossref","unstructured":"Zahran AM, Elsayh KI (2012) CD4+CD25+High FoxP3+ regulatory T cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut children hospital. Clin Appl Thromb Hemost. doi: 10.1177\/1076029612454937","DOI":"10.1177\/1076029612454937"},{"key":"615_CR19","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4103\/2230-8210.102998","volume":"16","author":"AM Zahran","year":"2012","unstructured":"Zahran AM, Elsayh KI, Metwalley KA (2012) Regulatory T cells in children with recently diagnosed type 1 diabetes. Indian J Endocr Metab 16:952\u2013957","journal-title":"Indian J Endocr Metab"},{"issue":"4","key":"615_CR20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"key":"615_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.coi.2008.04.008","volume":"2","author":"TJ Curiel","year":"2008","unstructured":"Curiel TJ (2008) Regulatory T cells and treatment of cancer. Curr Opin Immunol 2:241\u2013246","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"615_CR22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.exphem.2010.09.004","volume":"38","author":"JM Rojas","year":"2010","unstructured":"Rojas JM, Wang L, Owen S et al (2010) Naturally occurring CD4+CD25+FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol 38(12):1209\u20131218","journal-title":"Exp Hematol"},{"issue":"4","key":"615_CR23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3343\/kjlm.2011.31.4.231","volume":"31","author":"H Moon","year":"2011","unstructured":"Moon H, Kim BH, Park CM et al (2011) CD4+CD25highFoxP3+ Regulatory T-cells in Hematologic Diseases. Korean J Lab Med 31(4):231\u2013237","journal-title":"Korean J Lab Med"},{"key":"615_CR24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","volume":"112","author":"R Stasi","year":"2008","unstructured":"Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell depleting therapy with Rituximab. Blood 112:1147\u20131150","journal-title":"Blood"},{"key":"615_CR25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrc2439","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ (2008) How Tregs work. Nat Rev 8:523\u2013532","journal-title":"Nat Rev"},{"key":"615_CR26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi S (2004) Naturally arising CD4+ Tregs for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531\u2013562","journal-title":"Annu Rev Immunol"},{"key":"615_CR27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","volume":"4","author":"R Khattri","year":"2003","unstructured":"Khattri R, Cox T, Yasayko SA et al (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4:337\u2013342","journal-title":"Nat Immunol"},{"key":"615_CR28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057\u20131061","journal-title":"Science"},{"key":"615_CR29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","volume":"103","author":"S Appel","year":"2004","unstructured":"Appel S, Boehmler AM, Grunebach F (2004) Imatinib mesylate affects the development and function of dendritic cells generated from CD34 peripheral blood progenitor cells. Blood 103:538\u2013544","journal-title":"Blood"},{"key":"615_CR30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ni1179","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot JD, Rudensky AY (2005) A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 6:331\u2013337","journal-title":"Nat Immunol"},{"issue":"6","key":"615_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4110\/in.2009.9.6.209","volume":"9","author":"TY Ha","year":"2009","unstructured":"Ha TY (2009) The role of regulatory T cells in cancer. Immune Netw 9(6):209\u2013235","journal-title":"Immune Netw"},{"key":"615_CR32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1189\/jlb.0705419","volume":"79","author":"N Boissel","year":"2006","unstructured":"Boissel N, Rousselot P, Raffoux E (2006) Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell\u2013T cell activation. J Leukoc Biol 79:747\u2013756","journal-title":"J Leukoc Biol"},{"key":"615_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.705","volume":"21","author":"N Sato","year":"2003","unstructured":"Sato N, Narita M, Takahashi M (2003) The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 21:67\u201375","journal-title":"Hematol Oncol"},{"key":"615_CR34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13684730210002319","volume":"7","author":"JM Aswald","year":"2002","unstructured":"Aswald JM, Lipton JH, Aswald S et al (2002) Increased IFNgamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther 7:143\u2013149","journal-title":"Cytokines Cell Mol Ther"},{"key":"615_CR35","first-page":"1133","volume":"31","author":"J Chen","year":"2007","unstructured":"Chen J, Schmitt A, Giannopoulos K (2007) Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner. Int J Oncol 31:1133\u20131139","journal-title":"Int J Oncol"},{"key":"615_CR36","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","volume":"181","author":"N Larmonier","year":"2008","unstructured":"Larmonier N, Janikashvili N, LaCasse CJ (2008) Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-AB L- tumors. J Immunol 181:6955\u20136963","journal-title":"J Immunol"}],"updated-by":[{"DOI":"10.1007\/s10147-015-0813-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0615-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0615-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T20:35:51Z","timestamp":1596573351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0615-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,26]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0615-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10147-015-0813-8","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,26]]}}}